199 related articles for article (PubMed ID: 38093196)
21. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
Jacobsen P; Zhong W; Nomikos G; Clayton A
J Sex Med; 2019 Oct; 16(10):1638-1649. PubMed ID: 31405765
[TBL] [Abstract][Full Text] [Related]
22. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study.
McCue M; Sarkey S; Eramo A; François C; Parikh SV
BMC Psychiatry; 2021 Dec; 21(1):622. PubMed ID: 34895181
[TBL] [Abstract][Full Text] [Related]
23. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.
François C; Nielsen R; Danchenko N; Williams V; Lançon C
Curr Med Res Opin; 2017 Jun; 33(6):1057-1066. PubMed ID: 28277865
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
[TBL] [Abstract][Full Text] [Related]
25. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
Mattingly GW; Ren H; Christensen MC; Katzman MA; Polosan M; Simonsen K; Hammer-Helmich L
Front Psychiatry; 2022; 13():824831. PubMed ID: 35356713
[TBL] [Abstract][Full Text] [Related]
27. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.
Wang G; Xiao L; Ren H; Simonsen K; Ma J; Xu X; Guo P; Wang Z; Bai L; Heldbo Reines E; Hammer-Helmich L
Neuropsychiatr Dis Treat; 2022; 18():1939-1950. PubMed ID: 36065389
[TBL] [Abstract][Full Text] [Related]
29. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Christensen MC; Loft H; McIntyre RS
J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
[TBL] [Abstract][Full Text] [Related]
30. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
31. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
Papalexi E; Galanopoulos A; Kontis D; Markopoulou M; Balta G; Karavelas E; Panagiotidis P; Vlachos T; Ettrup A
BMC Psychiatry; 2022 Aug; 22(1):548. PubMed ID: 35962369
[TBL] [Abstract][Full Text] [Related]
33. Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy: Results of the VIVRE Study.
McIntyre RS; Florea I; Pedersen MM; Christensen MC
J Clin Psychiatry; 2023 May; 84(4):. PubMed ID: 37227402
[No Abstract] [Full Text] [Related]
34. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
Christensen MC; Schmidt S; Grande I
J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
[TBL] [Abstract][Full Text] [Related]
35. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
[TBL] [Abstract][Full Text] [Related]
37. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Vieta E; Sluth LB; Olsen CK
J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
[TBL] [Abstract][Full Text] [Related]
38. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
[TBL] [Abstract][Full Text] [Related]
39. Sexual function improves as depressive symptoms decrease during treatment with escitalopram: results of a naturalistic study of patients with major depressive disorder.
Weber S; Frokjaer VG; Armand S; Nielsen JH; Knudsen GM; Joergensen MB; Stenbaek DS; Giraldi A
J Sex Med; 2023 Feb; 20(2):161-169. PubMed ID: 36763929
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study.
De Filippis S; Pugliese A; Christensen MC; Rosso G; Di Nicola M; Simonsen K; Ren H
Neuropsychiatr Dis Treat; 2022; 18():1665-1677. PubMed ID: 35971416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
